Paediatric_and_adult_nasal_RNAseq___COVID19
Understanding infectivity, progression and disease severity of COVID-19 in children. Understanding infectivity, progression and disease severity of COVID-19 in children: It has been observed that COVID-19 infection appears to present with reduced clinical severity and prevalence within children (<18 years) compared to adults. This project as part of a national collaborative initiative seeks to answer this question. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/
- Type: Transcriptome Analysis
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001007718 | Illumina NovaSeq 6000 | 268 | |
EGAD00001015345 | Illumina NovaSeq 6000 | 17 |
Publications | Citations |
---|---|
Local and systemic responses to SARS-CoV-2 infection in children and adults.
Nature 602: 2022 321-327 |
158 |
Age-specific nasal epithelial responses to SARS-CoV-2 infection.
Nat Microbiol 9: 2024 1293-1311 |
4 |
Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19.
ERJ Open Res 10: 2024 919-2023 |
0 |